Arch Oncology thinks it can stand out in the red-hot CD47 field, and it's taking $105M in new cash to prove it
In the past few years, a spate of companies have jumped into the search for a cancer therapy that blocks CD47’s “don’t eat me” signal. A group of crossover investors is now betting $105 million on Arch Oncology’s play — but CEO Laurence Blumberg says he’s not planning on going public just yet.
The funds will back Arch’s Phase I/II candidate AO-176, which is being tested both on its own and in combination studies in patients with solid tumors and hematologic malignancies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,000+ biopharma pros reading Endpoints daily — and it's free.